Wall Street brokerages predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will announce sales of $2.92 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from $2.20 million to $4.27 million. The business is expected to report its next quarterly earnings results on Monday, March 9th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $7.81 million for the current fiscal year, with estimates ranging from $7.10 million to $9.17 million. For the next fiscal year, analysts expect that the company will post sales of $27.95 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales averages are an average based on a survey of research firms that cover Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The company had revenue of $1.45 million for the quarter, compared to analyst estimates of $3.56 million.

A number of equities analysts recently commented on the stock. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective (down from $12.00) on shares of Kala Pharmaceuticals in a research note on Monday, November 11th. Bank of America downgraded shares of Kala Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $6.00 in a research note on Tuesday, December 17th. Wedbush reiterated a “buy” rating and set a $51.00 price objective on shares of Kala Pharmaceuticals in a research note on Monday, December 23rd. Finally, ValuEngine downgraded shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Kala Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $15.88.

A number of institutional investors have recently made changes to their positions in KALA. Bank of Montreal Can grew its stake in Kala Pharmaceuticals by 148.5% during the second quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after buying an additional 2,399 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after buying an additional 5,806 shares in the last quarter. Marshall Wace LLP acquired a new stake in Kala Pharmaceuticals during the first quarter worth about $325,000. Charles Schwab Investment Management Inc. grew its stake in Kala Pharmaceuticals by 34.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock worth $328,000 after buying an additional 13,271 shares in the last quarter. Finally, Wedbush Securities Inc. grew its stake in Kala Pharmaceuticals by 163.9% during the third quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock worth $340,000 after buying an additional 55,410 shares in the last quarter. Hedge funds and other institutional investors own 67.24% of the company’s stock.

NASDAQ:KALA traded up $0.84 during mid-day trading on Tuesday, reaching $6.52. 1,216,149 shares of the company’s stock were exchanged, compared to its average volume of 777,858. Kala Pharmaceuticals has a one year low of $3.24 and a one year high of $9.25. The firm has a market capitalization of $196.21 million, a PE ratio of -2.26 and a beta of 2.16. The business’s fifty day simple moving average is $4.34 and its two-hundred day simple moving average is $4.44. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: S&P 500 Index

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.